Trial Scorecards

Trial Scorecard: GLOBAL LEADERS

Researchers compared 1 month of ticagrelor (Brilinta, AstraZeneca) with aspirin therapy followed by ticagrelor alone with 1 year of dual antiplatelet therapy followed by 1 year of aspirin monotherapy in patients undergoing PCI.

Trial Scorecard: GLOBAL LEADERS

Researchers compared 1 month of ticagrelor (Brilinta, AstraZeneca) with aspirin therapy followed by ticagrelor alone with 1 year of dual antiplatelet therapy followed by 1 year of aspirin monotherapy in patients undergoing PCI.

Trial Scorecard: GLOBAL LEADERS